Wave Life Sciences LTD 10-Q quarterly reports

Wave Life Sciences reports on its Q2 2026 financial results, highlighting advancements in its RNA medicines pipeline, including positive interim data for WVE-007 and WVE-006, alongside a significant increase in R&D expenses and a decrease in cash reserves.

Wave Life Sciences reported a significant increase in revenue for Q1 2026, driven by collaboration agreements, while net loss decreased compared to the prior year.

Wave Life Sciences announced significant positive clinical data across its pipeline, including first-in-human RNA editing proof-of-mechanism and favorable regulatory feedback, alongside a reduced net loss for Q3 2025.

Wave Life Sciences reported a significant increase in net loss for the first half of 2025, driven by higher research and development expenses, while simultaneously announcing positive clinical data and advancement across its obesity, AATD, DMD, and Huntington's disease programs.

Wave Life Sciences reports its financial results for the first quarter of 2025, detailing progress in its RNA medicines platform and clinical programs.

Wave Life Sciences announced positive clinical data from its Huntington's disease and AATD programs, along with a financial update for the third quarter of 2024.

Wave Life Sciences reported a net loss of $32.9 million for the second quarter of 2024, while highlighting progress in its clinical programs and collaborations.

Wave Life Sciences reported a net loss of $31.6 million for the first quarter of 2024, while advancing its pipeline of RNA therapeutics.